Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that a poster examining the effects of TONMYA® (cyclobenzaprine HCl sublingual tablets) on fibromyalgia symptoms and physical function will be presented at the International Association for the Study of Pain (IASP) 2026 World Congress on Pain, scheduled for Oct. 26-30, 2026, in Bangkok, Thailand. The presentation is significant because TONMYA received U.S. Food and Drug Administration approval on Aug. 15, 2025, and was commercially launched in the United States on Nov. 17, 2025, making it the first new treatment for fibromyalgia in more than 15 years.
For investors and patients alike, the upcoming poster at a major international pain conference underscores Tonix’s commitment to generating and disseminating clinical evidence for its flagship medicine. Fibromyalgia is a chronic condition affecting millions worldwide, and the lack of new therapies for over a decade has left a substantial unmet need. The data to be presented could further validate TONMYA’s role in managing symptoms and improving physical function, potentially bolstering physician confidence and payer coverage. Moreover, the presentation may enhance the company’s visibility among key opinion leaders and researchers, paving the way for broader adoption. As a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system and immunology treatments, Tonix is also maximizing the science behind TONMYA in Phase 2 trials for major depressive disorder and acute stress disorder, suggesting potential label expansion opportunities.
The IASP World Congress is a premier global event for pain research and treatment, attracting thousands of delegates. Presenting there places Tonix alongside leading pain specialists and may facilitate collaborations. The company’s CNS commercial infrastructure supports its marketed products, including acute migraine therapies Zembrace® SymTouch® and Tosymra®, and its pipeline includes TNX-2900 for Prader-Willi syndrome and immunology candidates TNX-4800 for Lyme disease prophylaxis and TNX-1500 for transplant rejection prevention. While these are investigational and not yet approved, the breadth of the pipeline highlights Tonix’s long-term growth potential.
For more details, the full press release is available at https://ibn.fm/jFHh3, and the latest news and updates relating to TNXP can be found in the company’s newsroom at https://ibn.fm/TNXP. The announcement was disseminated through TinyGems, a specialized communications platform for small-cap and mid-cap companies, which is part of the Dynamic Brand Portfolio at IBN. TinyGems leverages InvestorWire for wire distribution and offers services such as editorial syndication to 5,000+ outlets and social media distribution. Investors should review the full terms at https://www.TinyGems.com/Disclaimer.
